Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.47 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.44 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5951954 | 0.82 | PDE4D (0.50) | PKN1PKN2SIRT2SIRT1SIRT3 | |
| SCHEMBL13849246 | 0.79 | FLT3 (0.49) | — | |
| SCHEMBL4095689 | 0.76 | FLT3 (0.49) | PKN1PKN2SIRT2SIRT1SIRT3 | |
| SCHEMBL4091122 | 0.74 | SIRT2 (0.41) | DGAT1PKN1PKN2SIRT2SIRT1 | |
| SCHEMBL12108636 | 0.73 | PKN1 (0.45) | PKN1PKN2SIRT2SIRT1SIRT3 | |
| SCHEMBL1299865 | 0.72 | PKN1 (0.49) | PKN1PKN2SIRT2SIRT1SIRT3 | |
| SCHEMBL13850422 | 0.72 | AURKA (0.48) | DGAT1FGFR1KDRSOAT1SMN1; SMN2 | |
| SCHEMBL1300899 | 0.71 | RAB9A (0.49) | PKN1PKN2SIRT2SIRT1SIRT3 | |
| SCHEMBL4097487 | 0.71 | CHEK1 (0.51) | FGFR1KDRSMN1; SMN2BRD4AURKA | |
| SCHEMBL13849192 | 0.70 | FLT3 (0.46) | PKN1PKN2SIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERNALIS R & D LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERNALIS R & D LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| EP-1891048-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | Vernalis (R&D) Limited (GB) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006134318-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERNALIS R & D LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | PDK1, CHEK1, PDK3 | DGAT1 3340/4885PKN1 122/4885PKN2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.